Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03039439 · ClinicalTrials.gov registry record

Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors

A clinical trial of Primary Hyperparathyroidism and Parathyroid Gland Adenoma, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
310
Enrollment target
1
Study location

NCT03039439: Recruiting study of Primary Hyperparathyroidism and Parathyroid Gland Adenoma, sponsored by M.D. Anderson Cancer Center.

NCT03039439 is a study of Primary Hyperparathyroidism and Parathyroid Gland Adenoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 310 participants, below the 708-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03039439, a study of Primary Hyperparathyroidism and Parathyroid Gland Adenoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
310 participants
Enrollment target
1
Study location

Study Summary

This trial studies molecular and immunohistochemical profiling of tumors in patients with parathyroid tumors. Studying molecular and immunohistochemical profiling of tumors may help doctors avoid inconsistencies in diagnosis, unnecessary or incomplete surgery, surgical morbidity, psychological stress, and inadequate follow up.

Primary Outcome

Will be reported as 0 (negative), 1 (low intensity), 2 (medium intensity), or 3 (high intensity). Sensitivity, specificity, and accuracy will be reported for each cutoff for each biomarker separately to categorize tumor types. Receiver operating characteristic (ROC) analysis will be employed to graphically summarize the tradeoffs between sensitivity and specificity for different cutoffs. Several different combinations of tumor types are of interest: parathyroid carcinoma (PC) versus (vs.) atypic

Conditions Studied

Primary Hyperparathyroidism Parathyroid Gland Adenoma Parathyroid Gland Atypical Adenoma Parathyroid Gland Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Laboratory Biomarker Analysis

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 310 participants
Start Date 2015-11-24
Est. Completion 2028-11-30
M.D. Anderson Cancer Center

2,692 total trials

What NCT03039439 shows while recruiting

NCT03039439 is an observational study that tracks outcomes without assigning an intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, below the 708-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (56% lower).

The record links to 4 conditions, with Primary Hyperparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.

NCT03039439 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03039439 about?

NCT03039439 is a clinical study titled "Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors". This trial studies molecular and immunohistochemical profiling of tumors in patients with parathyroid tumors. Studying molecular and immunohistochemical profiling of tumors may help doctors avoid inconsistencies in diagnosis, unnecessary or incomplete surgery, surgical morbidity, psychological stres...

What is the current status of trial NCT03039439?

This trial is currently recruiting. The enrollment target is 310 participants. The study started on 2015-11-24. Estimated completion is 2028-11-30.

What conditions does trial NCT03039439 study?

This clinical trial studies the following conditions: Primary Hyperparathyroidism, Parathyroid Gland Adenoma, Parathyroid Gland Atypical Adenoma, Parathyroid Gland Carcinoma.

What interventions are being tested in trial NCT03039439?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER).

Who is sponsoring clinical trial NCT03039439?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03039439 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Primary Hyperparathyroidism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04178018 · 310 participants · NA

    Transvaginal Ultrasound and Photoacoustic Imaging of Ovary

  • NCT04878094 · 310 participants · Phase 3

    A Study of Intra-operative Imaging in Women With Ovarian Cancer

  • NCT05459233 · 310 participants · NA

    Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR

  • NCT06117683 · 310 participants · NA

    Non-inferiority Trial Between Sotair® Device Attached to Manual Resuscitator Versus Mechanical Ventilation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03039439

Source: ClinicalTrials.gov NCT03039439, the US trial registry maintained by the National Library of Medicine. NCT03039439 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.